Johnson Financial Group Inc. Buys 225 Shares of Eli Lilly and Company (NYSE:LLY)

Johnson Financial Group Inc. raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 3,972 shares of the company’s stock after purchasing an additional 225 shares during the quarter. Johnson Financial Group Inc.’s holdings in Eli Lilly and Company were worth $2,315,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in LLY. Norges Bank bought a new position in shares of Eli Lilly and Company during the 4th quarter worth about $5,992,890,000. International Assets Investment Management LLC boosted its position in shares of Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after acquiring an additional 7,330,815 shares in the last quarter. Sapient Capital LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $682,139,000. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at about $435,736,000. Finally, Vanguard Group Inc. boosted its position in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after acquiring an additional 659,838 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.1 %

Shares of LLY traded down $1.02 on Friday, reaching $807.43. 1,758,200 shares of the company’s stock were exchanged, compared to its average volume of 2,993,883. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The stock has a market capitalization of $767.39 billion, a P/E ratio of 118.91, a price-to-earnings-growth ratio of 1.75 and a beta of 0.37. The business has a 50 day moving average price of $765.47 and a two-hundred day moving average price of $692.32. Eli Lilly and Company has a 12 month low of $419.80 and a 12 month high of $820.60.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.62 earnings per share. Research analysts anticipate that Eli Lilly and Company will post 13.78 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on LLY shares. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research report on Wednesday, February 21st. Bank of America boosted their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $769.53.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.